Poly Medicure Q1 FY27 profit seen at ₹86 cr report

What is known so far

Poly Medicure’s Q1 FY27 consolidated net profit is reportedly ₹86 crore, according to a source alert, and the figure has not been independently verified against regulatory filings. The same alert benchmarks this against a consolidated net profit of ₹93.1 crore in Q1 FY26. The comparison matters because Q1 FY26 numbers are available as a verified reference point, while the Q1 FY27 profit figure is still awaiting formal disclosures. Until the company files its results with exchanges, the reported profit should be treated as preliminary. The company has, however, scheduled a formal management interaction to discuss the quarter. For investors, the near-term focus is on what is confirmed, what is pending, and what guidance implies about the year ahead.

Reported Q1 FY27 profit versus the verified base

The reported Q1 FY27 consolidated net profit of ₹86 crore implies a decline from the ₹93.1 crore posted in Q1 FY26. The ₹93.1 crore figure is repeatedly stated as the Q1 FY26 consolidated net profit baseline. In the same verified Q1 FY26 period, Poly Medicure’s results snapshot also lists EBITDA at ₹106.1 crore and total income at ₹444.9 crore, with an EBITDA margin of 26.3% and a PAT margin of 20.9%. Those prior-period metrics offer context for how operating performance and margins supported profitability last year.

But the key limitation remains that the current quarter’s ₹86 crore figure is described as “reportedly” and “not independently verified”. The article context explicitly notes that a definitive trading signal cannot be established without verification through primary regulatory filings. That makes the upcoming board meeting outcome and exchange filings critical for clarity on consolidated performance and any segment-level drivers.

Board meeting and results timeline

Poly Medicure has a board meeting scheduled for August 7, 2026, to approve the unaudited Q1 FY27 standalone and consolidated financial results. This date is also listed as the “Results date: August 07, 2026” in the quick details. The quarter in question is the first quarter ended June 30, 2026.

The company also implemented the standard regulatory trading window closure on July 1, 2026, during the preparation of results, as noted in the context. Such window closures are typical compliance steps around results finalisation. For market participants, the approval date is the first expected checkpoint, followed by the full set of financial statements and accompanying disclosures.

Earnings conference call details and participants

Poly Medicure will host an earnings conference call on Monday, August 10, 2026, from 4:00 PM to 5:00 PM IST to discuss its unaudited financial results for Q1 FY27. The announcement was filed with the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 5, 2026.

Management participants named for the call include Himanshu Baid, Naresh Vijayvergiya, and Rahul Gautam. The company communication also notes that investors can join through a universal dial-in number or via a registration link. For analysts, the call is typically where management commentary helps bridge gaps that headline numbers cannot explain, such as product mix, export trends, cost movements, and acquisition-related consolidation.

FY27 guidance sets a growth yardstick

Beyond the quarter, the company’s FY27 consolidated revenue guidance is stated at ₹2,300-₹2,400 crore, compared with ₹1,875 crore consolidated revenue reported for FY26. The FY26 figure is also supported by a revenue-from-operations number of ₹1,875.2592 crore for the year. On a standalone basis, revenue guidance is ₹1,900-₹1,950 crore, with domestic business expected to grow over 20% and international business over 15%, as cited in the context.

The guidance includes the full-year consolidation of acquisitions PendraCare and Citieffe. This is important because year-on-year comparisons can be influenced by changes in consolidation scope. In addition, consolidated EBITDA margin guidance is stated at 23%-25%, while standalone EBITDA margin is expected at 25%-27%, consistent with FY26.

Recent quarterly context from FY26 disclosures

The context includes several FY26 datapoints that help frame expectations. For Q4 FY26, consolidated revenue is cited around ₹534.5114 crore (also referenced as ₹534 crore), with a year-on-year increase of about 21.25% versus Q4 FY25 revenue-from-operations of ₹440.8282 crore. Q4 FY26 net profit is listed at ₹65.0410 crore, with the same disclosure set showing a full-year FY26 net profit of ₹320.7299 crore.

Separately, Q3 FY26 results in the context show revenue of ₹493.7 crore, EBITDA of ₹119.4 crore, and PAT of ₹70.8 crore, with an EBITDA margin of 24.2% and PAT margin of 13.6%. Together, these datapoints indicate that quarterly profitability and margins have varied across FY26 even as revenue grew year-on-year in reported quarters.

Key facts at a glance

Market impact: what investors can and cannot conclude now

Because the Q1 FY27 net profit of ₹86 crore is explicitly described as unverified against regulatory filings, the immediate market takeaway is about information quality rather than directional certainty. The context itself notes that a definitive trading signal cannot be established without verification of consolidated performance. That suggests the near-term market reaction, if any, should be interpreted cautiously until the company’s approved results are published.

At the same time, the FY27 consolidated revenue guidance of ₹2,300-₹2,400 crore sets an expectation framework against the FY26 base of ₹1,875 crore. Management also indicates the guidance is supported by domestic growth and by full-year consolidation of PendraCare and Citieffe, which may influence comparability. Investors typically use the earnings call to test whether quarterly execution is tracking to full-year targets, including the implied quarterly run-rate requirement mentioned as roughly ₹500-₹530 crore.

Why this update matters for Poly Medicure watchers

For Poly Medicure, a quarter where profit is reported lower year-on-year would raise questions around margins, costs, mix, and consolidation effects. However, the provided information does not include Q1 FY27 revenue, EBITDA, margins, or detailed segment commentary, so the reasons for the reported profit number cannot be concluded from the alert alone. The most actionable piece of information is the timetable: board approval on August 7, followed by management discussion on August 10.

The context also shows that FY26 had quarters with differing profit performance, including Q4 FY26 net profit of ₹65.0410 crore and Q3 FY26 PAT of ₹70.8 crore, while Q1 FY26 PAT was ₹93.1 crore. That spread underlines why investors generally wait for the full quarterly statement and notes, rather than rely on a single headline figure.

What to watch next

The next confirmed milestone is the board meeting scheduled for August 7, 2026, to approve unaudited Q1 FY27 standalone and consolidated results. After that, the August 10, 2026 earnings call with Himanshu Baid, Naresh Vijayvergiya, and Rahul Gautam is expected to provide management’s explanation of quarterly performance and how it aligns with FY27 guidance. Until the official filing is available, the reported ₹86 crore net profit figure should be treated as provisional.